BetaEntity Annotation Prototype

Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

4articles mentioning diseases
4disease mentions
1distinct diseases extracted
0%of mentions human-reviewed
Active filtersEntity: Immune effector cell-associated neurotoxicity syndrome (ICANS) ×

Immune effector cell-associated neurotoxicity syndrome (ICANS)

This disease is selected. Its supporting articles are shown below.

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)4

Articles mentioning Immune effector cell-associated neurotoxicity syndrome (ICANS)

4 articles · page 1 of 1
81.9%
multiple myelomaDLBCLacute lymphoblastic leukaemiadiffuse large B-cell lymphomaICANSMMALLcytokine release syndromeimmune effector cell-associated neurotoxicity syndrome (ICANS)

…= 53, 76%), acute lymphoblastic leukaemia (ALL, n = 6, 9%), and multiple myeloma (MM, n = 6, 9%). CAR-T products: axicabtagene ciloleucel (n = 3…

90.1%
haematological malignanciesImmune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)ICANSChimeric Antigen Receptor T-cell (CAR-T) therapyCAR-T therapy

…ptor T-cell (CAR-T) therapy has revolutionised the treatment of haematological malignancies. Despite its efficacy, CAR-T therapy is associated with a high …

92.6%
haematological cancersImmune effector cell-associated neurotoxicity syndrome (ICANS)The Alfred Hospitalchimeric antigen receptor T-cell (CAR-T) therapyCAR-T therapy

…ated the utility of the CDT in detecting ICANS in patients with haematological cancers following CAR-T therapy.Methods Data were collected from CAR-T …

88.4%
haematological malignanciesautoimmune neurological disordersICANSimmune effector cell-associated neurotoxicity syndrome (ICANS)ICANS-relatedChimeric antigen receptor T-cell (CAR-T) therapyThe Alfred Hospital

…cell (CAR-T) therapy has transformed the treatment landscape of haematological malignancies and is being trialled for autoimmune neurological disorders. Ho…